Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia

Table 1

Phase 1 clinical trials using anti-CD19 CAR modified T cells for the treatment of B-cell malignancies (updated and adapted from [49]).

Disease	CAR configuration	Preconditioning	Status of trial	Clinical trials.gov identifier	Clinical trial centre
B-CLL	scFv-CD28-CD3ζ	none versus cyclophosphamide	recruiting	NCT00466531	Memorial Sloan-Kettering Cancer Center
B-ALL	scFv-CD28-CD3ζ	none	recruiting	NCT00709033	Baylor College of Medicine
B-NHL, B-CLL	scFv-CD28-CD3ζ  versus scFv-CD3ζ	none	recruiting	NCT00586391	Baylor College of Medicine
B-NHL, B-CLL	scFv-CD28-CD3ζ  versus EBV/scFv-CD3ζ	none	recruiting	NCT00608270	Baylor College of Medicine
B-ALL	scFv-CD28-CD3ζ	cyclophosphamide	recruiting	NCT01044069	Memorial Sloan-Kettering Cancer Center
B-lymphoma, B-CLL	scFv-CD28-CD3ζ	fludarabine plus cyclophosphamide	recruiting	NCT00924326	National Cancer Institute
B-lymphoma/leukemia	scFv-41BB-CD3ζ  versus scFv-CD3ζ	variable		NCT00891215	The University of Pennsylvania
B-NHL	scFv-CD28-CD3ζ	BEAM-R		NCT00968760	MD Anderson Cancer Center
refractory B-cell lymphoma/leukemia	scFv-CD3ζ	fludarabine plus low dose cyclophosphamide	recruiting		The University of Manchester, UK